Skip to main content
Top
Published in: Hepatology International 1/2024

12-09-2023 | Liver Transplantation | Original Article

Propensity score matched analysis and risk stratification of donors with G6PD deficiency in living donor liver transplantation

Authors: P. Krishna, A. Rammohan, R. Rajalingam, G. Narasimhan, R. Cherukuru, D. Sachan, A. Rajakumar, I. Kaliamoorthy, M. S. Reddy, M. Rela

Published in: Hepatology International | Issue 1/2024

Login to get access

Abstract

Introduction

Glucose 6 phosphate dehydrogenase (G6PD) deficiency (G6PDd) can trigger hemolysis following surgical stress. Differentiating G6PDd-related post-operative hemolytic episodes (PHE) and post-hepatectomy liver failure may be challenging especially in living donors where donor safety is paramount. We analysed outcomes of our cohort of G6PDd liver donors.

Methods

G6PDd individuals with no evidence of hemolysis were considered as living donors if there was no alternative family donor. Outcomes of G6PDd donors undergoing left lateral/left lobe donation (Group LL) and right lobe donation (Group RL) were compared with non-G6PDd donors matched in a 1:3 ratio using propensity score matching.

Results

59 G6PDd donors (5.8% of 1011) underwent living donor hepatectomy (LiDH) during the study period. LL-G6PDd donors (22.37%) had higher post-operative peak bilirubin level compared to matched controls, but no difference in morbidity or need for post-operative blood transfusion.RL-G6PDd donors (37.63%) had higher peak bilirubin level, morbidity (16.2% vs. 3.6%, p = 0.017) and more post-operative blood transfusion (21.6% vs. 6.4%, p = 0.023) as compared to matched non-G6PDd cohort. Four RL-G6PDd donors (10.8%) developed PHE. Low G6PD activity (15% vs. 40%, p = 0.034) and lower future liver remnant (FLR) (34.3% vs. 37.8%, p = 0.05) were identified as risk factors for PHE.

Conclusion

We report the largest to-date series of G6PDd individuals undergoing LiDH and confirm the safety of LL donation in G6PDd. Our analysis identifies specific risk factors for PHE and suggests that right lobe LiDH be avoided in individuals with less than 25% G6PD activity when the FLR is less than 36%.
Literature
1.
go back to reference Rela M, Reddy MS. Living donor liver transplant (LDLT) is the way forward in Asia. Hepatol Int. 2017;11:148–151CrossRefPubMed Rela M, Reddy MS. Living donor liver transplant (LDLT) is the way forward in Asia. Hepatol Int. 2017;11:148–151CrossRefPubMed
2.
go back to reference Rela M, Rammohan A. Why are there so many liver transplants from living donors in Asia and so few in Europe and the US? J Hepatol. 2021;75:975–980CrossRefPubMed Rela M, Rammohan A. Why are there so many liver transplants from living donors in Asia and so few in Europe and the US? J Hepatol. 2021;75:975–980CrossRefPubMed
4.
go back to reference Narasimhan G, Safwan M, Kota V, Reddy MS, Bharathan A, Dabora A, et al. Donor outcomes in living donor liver transplantation-analysis of 275 donors from a single centre in India. Transplantation. 2016;100:1251–1256CrossRefPubMed Narasimhan G, Safwan M, Kota V, Reddy MS, Bharathan A, Dabora A, et al. Donor outcomes in living donor liver transplantation-analysis of 275 donors from a single centre in India. Transplantation. 2016;100:1251–1256CrossRefPubMed
5.
go back to reference Rammohan A, Reddy MS, Narasimhan G, Rajalingam R, Kaliamoorthy I, Krishnan M, et al. Live liver donors: is right still right? World J Surg. 2020;44:2385–2393CrossRefPubMed Rammohan A, Reddy MS, Narasimhan G, Rajalingam R, Kaliamoorthy I, Krishnan M, et al. Live liver donors: is right still right? World J Surg. 2020;44:2385–2393CrossRefPubMed
6.
go back to reference Shenkutie TT, Nega D, Hailu A, Kepple D, Witherspoon L, Lo E, et al. Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre. Eastern Ethiopia Malar J. 2022;21:260PubMed Shenkutie TT, Nega D, Hailu A, Kepple D, Witherspoon L, Lo E, et al. Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre. Eastern Ethiopia Malar J. 2022;21:260PubMed
7.
go back to reference Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. Chapter Four—G6PD deficiency: global distribution, genetic variants and primaquine therapy. In Hay SI, Price R, Baird JKBT-A, editors., Epidemiol plasmodium vivax. Cambridge: Academic Press; 2013. 133–201CrossRef Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. Chapter Four—G6PD deficiency: global distribution, genetic variants and primaquine therapy. In Hay SI, Price R, Baird JKBT-A, editors., Epidemiol plasmodium vivax. Cambridge: Academic Press; 2013. 133–201CrossRef
8.
go back to reference Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42:267–278CrossRefPubMed Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42:267–278CrossRefPubMed
9.
go back to reference Lee HY, Ithnin A, Azma RZ, Othman A, Salvador A, Cheah FC. Glucose-6-phosphate dehydrogenase deficiency and neonatal hyperbilirubinemia: insights on pathophysiology, diagnosis, and gene variants in disease heterogeneity. Front Pediatr. 2022;10: 875877CrossRefPubMedPubMedCentral Lee HY, Ithnin A, Azma RZ, Othman A, Salvador A, Cheah FC. Glucose-6-phosphate dehydrogenase deficiency and neonatal hyperbilirubinemia: insights on pathophysiology, diagnosis, and gene variants in disease heterogeneity. Front Pediatr. 2022;10: 875877CrossRefPubMedPubMedCentral
10.
go back to reference Luzzatto L, Nannelli C, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Hematol Oncol Clin North Am. 2016;30:373–393CrossRefPubMed Luzzatto L, Nannelli C, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Hematol Oncol Clin North Am. 2016;30:373–393CrossRefPubMed
11.
go back to reference Dogar AW, Ullah K, Ghaffar A, Ud-Din S, Hussain A, Ahmed HB, et al. Safety of glucose-6 phosphate dehydrogenase deficient donors in living right lobe liver donation. Clin Transplant. 2022;36:e14627CrossRefPubMed Dogar AW, Ullah K, Ghaffar A, Ud-Din S, Hussain A, Ahmed HB, et al. Safety of glucose-6 phosphate dehydrogenase deficient donors in living right lobe liver donation. Clin Transplant. 2022;36:e14627CrossRefPubMed
12.
go back to reference Reddy MS, Shrivastav M, Kaliamoorthy I, Kota V, Dabora A, Govil S, et al. Safety of live liver donation by individuals with G6PD deficiency: initial results and comparative study. Transplantation. 2016;100:814–818CrossRefPubMed Reddy MS, Shrivastav M, Kaliamoorthy I, Kota V, Dabora A, Govil S, et al. Safety of live liver donation by individuals with G6PD deficiency: initial results and comparative study. Transplantation. 2016;100:814–818CrossRefPubMed
13.
go back to reference Elyassi AR, Rowshan HH. Perioperative management of the glucose-6-phosphate dehydrogenase deficient patient: a review of literature. Anesth Prog. 2009;56:86–91CrossRefPubMedPubMedCentral Elyassi AR, Rowshan HH. Perioperative management of the glucose-6-phosphate dehydrogenase deficient patient: a review of literature. Anesth Prog. 2009;56:86–91CrossRefPubMedPubMedCentral
14.
go back to reference Goralczyk AD, Moser C, Scherer MN, Tsui TY, Doenecke A, Lorf T, et al. Glucose-6-phosphate dehydrogenase deficiency: a contraindication for living donor liver transplantation? Transpl Int Off J Eur Soc Organ Transplant Switzerland. 2010;23:e65–e66CrossRef Goralczyk AD, Moser C, Scherer MN, Tsui TY, Doenecke A, Lorf T, et al. Glucose-6-phosphate dehydrogenase deficiency: a contraindication for living donor liver transplantation? Transpl Int Off J Eur Soc Organ Transplant Switzerland. 2010;23:e65–e66CrossRef
16.
go back to reference Zailani MAH, Raja Sabudin RZA, Ithnin A, Alauddin H, Sulaiman SA, Ismail E, et al. Population screening for glucose-6-phosphate dehydrogenase deficiency using quantitative point-of-care tests: a systematic review. Front Genet Switz. 2023;14:1098828CrossRef Zailani MAH, Raja Sabudin RZA, Ithnin A, Alauddin H, Sulaiman SA, Ismail E, et al. Population screening for glucose-6-phosphate dehydrogenase deficiency using quantitative point-of-care tests: a systematic review. Front Genet Switz. 2023;14:1098828CrossRef
17.
go back to reference Pfeffer DA, Ley B, Howes RE, Adu P, Alam MS, Bansil P, et al. Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: a systematic review and meta-analysis. PLoS Med. 2020;17: e1003084CrossRefPubMedPubMedCentral Pfeffer DA, Ley B, Howes RE, Adu P, Alam MS, Bansil P, et al. Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: a systematic review and meta-analysis. PLoS Med. 2020;17: e1003084CrossRefPubMedPubMedCentral
18.
go back to reference Yang JY, Webster-Clark M, Lund JL, Sandler RS, Dellon ES, Stürmer T. Propensity score methods to control for confounding in observational cohort studies: a statistical primer and application to endoscopy research. Gastrointest Endosc. 2019;90:360–369CrossRefPubMedPubMedCentral Yang JY, Webster-Clark M, Lund JL, Sandler RS, Dellon ES, Stürmer T. Propensity score methods to control for confounding in observational cohort studies: a statistical primer and application to endoscopy research. Gastrointest Endosc. 2019;90:360–369CrossRefPubMedPubMedCentral
20.
go back to reference Clavien PA, Barkun J, De Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The clavien-dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–196CrossRefPubMed Clavien PA, Barkun J, De Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The clavien-dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–196CrossRefPubMed
21.
go back to reference Belfield KD, Tichy EM. Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency. Am J Heal Pharm AJHP Off J Am Soc Heal Pharm. 2018;75:97–104 Belfield KD, Tichy EM. Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency. Am J Heal Pharm AJHP Off J Am Soc Heal Pharm. 2018;75:97–104
22.
go back to reference Samanta S, Kumar P, Kishore SS, Garewal G, Narang A. Donor blood glucose 6-phosphate dehydrogenase deficiency reduces the efficacy of exchange transfusion in neonatal hyperbilirubinemia. Pediatrics. 2009;123:e96-100CrossRefPubMed Samanta S, Kumar P, Kishore SS, Garewal G, Narang A. Donor blood glucose 6-phosphate dehydrogenase deficiency reduces the efficacy of exchange transfusion in neonatal hyperbilirubinemia. Pediatrics. 2009;123:e96-100CrossRefPubMed
23.
go back to reference Renzaho AMN, Husser E, Polonsky M. Should blood donors be routinely screened for glucose-6-phosphate dehydrogenase deficiency? A systematic review of clinical studies focusing on patients transfused with glucose-6-phosphate dehydrogenase-deficient red cells. Transfus Med Rev. 2014;28:7–17CrossRefPubMed Renzaho AMN, Husser E, Polonsky M. Should blood donors be routinely screened for glucose-6-phosphate dehydrogenase deficiency? A systematic review of clinical studies focusing on patients transfused with glucose-6-phosphate dehydrogenase-deficient red cells. Transfus Med Rev. 2014;28:7–17CrossRefPubMed
24.
go back to reference Garcia AA, Koperniku A, Ferreira JCB, Mochly-Rosen D. Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives. Trends Pharmacol Sci. 2021;42:829–844CrossRefPubMedPubMedCentral Garcia AA, Koperniku A, Ferreira JCB, Mochly-Rosen D. Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives. Trends Pharmacol Sci. 2021;42:829–844CrossRefPubMedPubMedCentral
Metadata
Title
Propensity score matched analysis and risk stratification of donors with G6PD deficiency in living donor liver transplantation
Authors
P. Krishna
A. Rammohan
R. Rajalingam
G. Narasimhan
R. Cherukuru
D. Sachan
A. Rajakumar
I. Kaliamoorthy
M. S. Reddy
M. Rela
Publication date
12-09-2023
Publisher
Springer India
Published in
Hepatology International / Issue 1/2024
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10583-0

Other articles of this Issue 1/2024

Hepatology International 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.